Back to resultsA Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (SURPASS-SWITCH)
Primary Purpose
Type 2 Diabetes
Status
Recruiting
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Tirzepatide
Dulaglutide
Sponsored by
About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Have type 2 diabetes
- Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol)
- Are currently on a stable dose of dulaglutide weekly (0.75 mg or 1.5 mg) for at least 6 months prior to screening.
- No treatment with oral antihyperglycemic medication (OAM), or on a stable dose of up to 3 OAMs, which may include metformin, sodium glucose cotransporter-2 inhibitors (SGLT-2i), and/or sulfonylurea, for at least 3 months before screening.
- Have had stable body weight (±5%) during the 90 days preceding screening
- Have BMI ≥25 kilogram/square meter (kg/m²)
Exclusion Criteria:
- Have type 1 diabetes
- Have a history of chronic or acute pancreatitis
Have a history of
- proliferative diabetic retinopathy, or
- diabetic maculopathy, or
- nonproliferative diabetic retinopathy that requires acute treatment.
Have any of these cardiovascular (CV) conditions within 60 days prior to screening:
- acute myocardial infarction,
- cerebrovascular accident (stroke), or
- hospitalization due to congestive heart failure (CHF).
- Have New York Heart Assocation (NYHA) Functional Classification Class IV CHF
- Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
- Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over-the-counter, or alternative remedies
- Have an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label)
Have been treated with insulin prior to screening
- Exception: use of insulin for gestational diabetes or short-term use (<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery.
- Have a history of reduction of dose of dulaglutide, due to intolerability, without successful reescalation
Sites / Locations
- ALL Medical Research, LLCRecruiting
- Metabolic Research Institute, Inc.Recruiting
- NorthShore University Health SystemRecruiting
- Iowa Diabetes and Endocrinology Research CenterRecruiting
- Clinvest Research LLCRecruiting
- Alliance for Multispecialty Research, LLCRecruiting
- Juno ResearchRecruiting
- Biopharma Informatic, LLCRecruiting
- Juno ResearchRecruiting
- Southern Endocrinology AssociatesRecruiting
- North Hills Family Medicine/North Hills Medical ResearchRecruiting
- Imelda General HospitalRecruiting
- Antwerp University HospitalRecruiting
- ZNA Jan PalfijnRecruiting
- Az Damiaan vzwRecruiting
- Hôpital de la ConceptionRecruiting
- CHU RangueilRecruiting
- CHU Montpellier Lapeyronie HospitalRecruiting
- Groupe Hospitalier Mutualiste Les Portes du SudRecruiting
- Centre Hospitalier Sud FrancilienRecruiting
- Groupe hospitalier Paris saint JosephRecruiting
- Medizinisches Versorgungszentrum am Bahnhof Spandau
- InnoDiab Forschung Gmbh
- Institut für Diabetesforschung GmbH Münster
- RED-Institut GmbH
- Diabeteszentrum Hamburg West
- Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades CardiovascularesRecruiting
- Diseno y Planeacion en Investigacion MedicaRecruiting
- Unidad de Investigación Clínica y Atención Médica HEPARecruiting
- Instituto de Diabetes, Obesidad y NutricionRecruiting
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"Recruiting
- Unidad biomedica avanzada monterreyRecruiting
- Centro de Estudios de Investigacion Metabolicos y CardiovascularesRecruiting
- Investigacion En Salud Y Metabolismo ScRecruiting
- DiabdanaRecruiting
- Mariodiab ClinicRecruiting
- Geea Medical Easy DietRecruiting
- Gama DiamedRecruiting
- CMI DNBM Dr. Pop LaviniaRecruiting
- Clinica KorallRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Tirzepatide
Dulaglutide
Arm Description
Participants will receive tirzepatide subcutaneously (SC)
Participants will escalate their dulaglutide dose SC.
Outcomes
Primary Outcome Measures
Change from Baseline in Hemoglobin A1c (HbA1c)
Secondary Outcome Measures
Change from Baseline in Weight
Percentage of Participants Who Achieve HbA1c <7%
Percentage of Participants Who Achieve HbA1c ≤6.5%
Percentage of Participants Who Achieve HbA1c <5.7%
Percentage of Participants Who Achieve Weight loss from Baseline of ≥5%
Percentage of Participants Who Achieve Weight loss from baseline of ≥10%
Percentage of Participants Who Achieve Weight loss from baseline of ≥15%
A Composite Endpoint of HbA1c, Weight loss and Hypoglycemia
A composite endpoint defined as HbA1c ≤ 6.5%, weight loss ≥10%, no hypoglycemia, defined as blood glucose (BG) <54 milligram/deciliter (mg/dL) <3.0 millimole/liter (mmol/L) and/or severe hypoglycemia
Change from Baseline in Fasting Serum Glucose (FSG)
Change from Baseline in Waist Circumference
Change from Baseline in Body Mass Index (BMI)
Change from Baseline in Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score
Full Information
NCT ID
NCT05564039
First Posted
September 30, 2022
Last Updated
October 18, 2023
Sponsor
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT05564039
Brief Title
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Acronym
SURPASS-SWITCH
Official Title
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 30, 2022 (Actual)
Primary Completion Date
August 1, 2024 (Anticipated)
Study Completion Date
August 29, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
250 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Tirzepatide
Arm Type
Experimental
Arm Description
Participants will receive tirzepatide subcutaneously (SC)
Arm Title
Dulaglutide
Arm Type
Active Comparator
Arm Description
Participants will escalate their dulaglutide dose SC.
Intervention Type
Drug
Intervention Name(s)
Tirzepatide
Other Intervention Name(s)
LY3298176
Intervention Description
Administered SC
Intervention Type
Drug
Intervention Name(s)
Dulaglutide
Other Intervention Name(s)
LY2189265
Intervention Description
Administered SC
Primary Outcome Measure Information:
Title
Change from Baseline in Hemoglobin A1c (HbA1c)
Time Frame
Baseline, Week 40
Secondary Outcome Measure Information:
Title
Change from Baseline in Weight
Time Frame
Baseline, Week 40
Title
Percentage of Participants Who Achieve HbA1c <7%
Time Frame
Baseline to Week 40
Title
Percentage of Participants Who Achieve HbA1c ≤6.5%
Time Frame
Baseline to Week 40
Title
Percentage of Participants Who Achieve HbA1c <5.7%
Time Frame
Baseline to Week 40
Title
Percentage of Participants Who Achieve Weight loss from Baseline of ≥5%
Time Frame
Baseline to Week 40
Title
Percentage of Participants Who Achieve Weight loss from baseline of ≥10%
Time Frame
Baseline to Week 40
Title
Percentage of Participants Who Achieve Weight loss from baseline of ≥15%
Time Frame
Baseline to Week 40
Title
A Composite Endpoint of HbA1c, Weight loss and Hypoglycemia
Description
A composite endpoint defined as HbA1c ≤ 6.5%, weight loss ≥10%, no hypoglycemia, defined as blood glucose (BG) <54 milligram/deciliter (mg/dL) <3.0 millimole/liter (mmol/L) and/or severe hypoglycemia
Time Frame
Week 40
Title
Change from Baseline in Fasting Serum Glucose (FSG)
Time Frame
Baseline, Week 40
Title
Change from Baseline in Waist Circumference
Time Frame
Baseline, Week 40
Title
Change from Baseline in Body Mass Index (BMI)
Time Frame
Baseline, Week 40
Title
Change from Baseline in Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite CT) - Physical Functioning Score
Time Frame
Baseline, Week 40
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have type 2 diabetes
Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol)
Are currently on a stable dose of dulaglutide weekly (0.75 mg or 1.5 mg) for at least 6 months prior to screening.
No treatment with oral antihyperglycemic medication (OAM), or on a stable dose of up to 3 OAMs, which may include metformin, sodium glucose cotransporter-2 inhibitors (SGLT-2i), and/or sulfonylurea, for at least 3 months before screening.
Have had stable body weight (±5%) during the 90 days preceding screening
Have BMI ≥25 kilogram/square meter (kg/m²)
Exclusion Criteria:
Have type 1 diabetes
Have a history of chronic or acute pancreatitis
Have a history of
proliferative diabetic retinopathy, or
diabetic maculopathy, or
nonproliferative diabetic retinopathy that requires acute treatment.
Have any of these cardiovascular (CV) conditions within 60 days prior to screening:
acute myocardial infarction,
cerebrovascular accident (stroke), or
hospitalization due to congestive heart failure (CHF).
Have New York Heart Assocation (NYHA) Functional Classification Class IV CHF
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over-the-counter, or alternative remedies
Have an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label)
Have been treated with insulin prior to screening
Exception: use of insulin for gestational diabetes or short-term use (<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery.
Have a history of reduction of dose of dulaglutide, due to intolerability, without successful reescalation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone
1-317-615-4559
Email
ClinicalTrials.gov@lilly.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
ALL Medical Research, LLC
City
Cooper City
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
754-263-2000
First Name & Middle Initial & Last Name & Degree
Ana Lorena Lewy-Alterbaum
Facility Name
Metabolic Research Institute, Inc.
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
5618023060
First Name & Middle Initial & Last Name & Degree
Barry Scot Horowitz, MD
Facility Name
NorthShore University Health System
City
Skokie
State/Province
Illinois
ZIP/Postal Code
60077
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
8476638540
First Name & Middle Initial & Last Name & Degree
Liana Katz Billings
Facility Name
Iowa Diabetes and Endocrinology Research Center
City
West Des Moines
State/Province
Iowa
ZIP/Postal Code
50265
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
515-329-6800
First Name & Middle Initial & Last Name & Degree
Anuj Bhargava
Facility Name
Clinvest Research LLC
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65807
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
4178837889
First Name & Middle Initial & Last Name & Degree
David Gregory True
Facility Name
Alliance for Multispecialty Research, LLC
City
Norman
State/Province
Oklahoma
ZIP/Postal Code
73069
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
405-701-8999
First Name & Middle Initial & Last Name & Degree
Lisa Connery
Facility Name
Juno Research
City
Houston
State/Province
Texas
ZIP/Postal Code
77040
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
713-779-5494
First Name & Middle Initial & Last Name & Degree
Damaris Vega
Facility Name
Biopharma Informatic, LLC
City
Houston
State/Province
Texas
ZIP/Postal Code
77043
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Agadadash Kuliev, MD
Facility Name
Juno Research
City
Houston
State/Province
Texas
ZIP/Postal Code
77054
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rocio Harbison
Facility Name
Southern Endocrinology Associates
City
Mesquite
State/Province
Texas
ZIP/Postal Code
75149
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
214-693-0904
First Name & Middle Initial & Last Name & Degree
Sumana Gangi
Facility Name
North Hills Family Medicine/North Hills Medical Research
City
North Richland Hills
State/Province
Texas
ZIP/Postal Code
76180
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
817-595-3399
First Name & Middle Initial & Last Name & Degree
John Gabriel
Facility Name
Imelda General Hospital
City
Bonheiden
State/Province
Antwerpen
ZIP/Postal Code
2820
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
Phone
003215505164
First Name & Middle Initial & Last Name & Degree
Chris Vercammen
Facility Name
Antwerp University Hospital
City
Edegem
State/Province
Antwerpen
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
Phone
00328214364
First Name & Middle Initial & Last Name & Degree
Christophe E.M. De Block
Facility Name
ZNA Jan Palfijn
City
Merksem
State/Province
Vlaams Gewest
ZIP/Postal Code
2170
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
Phone
3236402817
First Name & Middle Initial & Last Name & Degree
ann verhaegen
Facility Name
Az Damiaan vzw
City
Oostende
State/Province
West-Vlaanderen
ZIP/Postal Code
8400
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
Phone
059414160
First Name & Middle Initial & Last Name & Degree
Linsey Winne
Facility Name
Hôpital de la Conception
City
Marseille
State/Province
Bouches-du-Rhône
ZIP/Postal Code
13005
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33491383653
First Name & Middle Initial & Last Name & Degree
Patrice Darmon
Facility Name
CHU Rangueil
City
Toulouse cedex 9
State/Province
Haute-Garonne
ZIP/Postal Code
31059
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
3356132321
First Name & Middle Initial & Last Name & Degree
Pierre Gourdy
Facility Name
CHU Montpellier Lapeyronie Hospital
City
Montpellier
State/Province
Hérault
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33467338402
First Name & Middle Initial & Last Name & Degree
ariane Sultan
Facility Name
Groupe Hospitalier Mutualiste Les Portes du Sud
City
Vénissieux
State/Province
Rhône-Alpes
ZIP/Postal Code
69200
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33472898975
First Name & Middle Initial & Last Name & Degree
Lucien MARCHAND
Facility Name
Centre Hospitalier Sud Francilien
City
Corbeil-Essonnes
State/Province
Île-de-France
ZIP/Postal Code
91106
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alfred Penfornis
Facility Name
Groupe hospitalier Paris saint Joseph
City
Paris
State/Province
Île-de-France
ZIP/Postal Code
75014
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33144127816
First Name & Middle Initial & Last Name & Degree
Olivier Dupuy
Facility Name
Medizinisches Versorgungszentrum am Bahnhof Spandau
City
Spandau
State/Province
Berlin
ZIP/Postal Code
13597
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
InnoDiab Forschung Gmbh
City
Essen
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
45136
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Institut für Diabetesforschung GmbH Münster
City
Münster
State/Province
Nordrhein-
ZIP/Postal Code
48145
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
RED-Institut GmbH
City
Oldenburg
State/Province
Schleswig-Holstein
ZIP/Postal Code
23758
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Diabeteszentrum Hamburg West
City
Hamburg
ZIP/Postal Code
22607
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
City
Mexico City
State/Province
Distrito Federal
ZIP/Postal Code
11650
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
Phone
525585340943
First Name & Middle Initial & Last Name & Degree
Melchor Alpizar
Facility Name
Diseno y Planeacion en Investigacion Medica
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44130
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
Phone
5233305493
First Name & Middle Initial & Last Name & Degree
Cesar Gonzalo Calvo
Facility Name
Unidad de Investigación Clínica y Atención Médica HEPA
City
Guadalajara
State/Province
Jalisco
ZIP/Postal Code
44670
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
Phone
523336422886
First Name & Middle Initial & Last Name & Degree
Marisol Herrera Marmolejo
Facility Name
Instituto de Diabetes, Obesidad y Nutricion
City
Cuernavaca
State/Province
Morelos
ZIP/Postal Code
62250
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leobardo Sauque Reyna
Facility Name
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
City
Monterrey
State/Province
Nuevo León
ZIP/Postal Code
64460
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jose Gerardo Gonzalez-Gonzalez
Facility Name
Unidad biomedica avanzada monterrey
City
Monterrey
State/Province
Nuevo León
ZIP/Postal Code
64460
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
Phone
8113578896
First Name & Middle Initial & Last Name & Degree
Raymundo Garcia Reza
Facility Name
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares
City
Ciudad Madero
State/Province
Tamaulipas
ZIP/Postal Code
89440
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
Phone
52183312600
First Name & Middle Initial & Last Name & Degree
Rafael Margarito Violante Ortiz
Facility Name
Investigacion En Salud Y Metabolismo Sc
City
Chihuahua
ZIP/Postal Code
31217
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
Phone
526144398618
First Name & Middle Initial & Last Name & Degree
Luis Alejandro Nevarez
Facility Name
Diabdana
City
Oradea
State/Province
Bihor
ZIP/Postal Code
410147
Country
Romania
Individual Site Status
Recruiting
Facility Contact:
Phone
004072248022
First Name & Middle Initial & Last Name & Degree
Dana Cosma
Facility Name
Mariodiab Clinic
City
Brasov
State/Province
Brașov
ZIP/Postal Code
500097
Country
Romania
Individual Site Status
Recruiting
Facility Contact:
Phone
40762249010
First Name & Middle Initial & Last Name & Degree
Brindusa Cofaru
Facility Name
Geea Medical Easy Diet
City
Bucharest
State/Province
București
ZIP/Postal Code
010627
Country
Romania
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georgeta Vacaru
Facility Name
Gama Diamed
City
Mangalia
State/Province
Constanța
ZIP/Postal Code
905500
Country
Romania
Individual Site Status
Recruiting
Facility Contact:
Phone
0040241740581
First Name & Middle Initial & Last Name & Degree
Amalia Drobeta Thury-Burileanu
Facility Name
CMI DNBM Dr. Pop Lavinia
City
Baia Mare
State/Province
Maramureș
ZIP/Postal Code
430222
Country
Romania
Individual Site Status
Recruiting
Facility Contact:
Phone
40735867270
First Name & Middle Initial & Last Name & Degree
Lavinia Pop
Facility Name
Clinica Korall
City
Satu Mare
ZIP/Postal Code
440055
Country
Romania
Individual Site Status
Recruiting
Facility Contact:
Phone
40741135808
First Name & Middle Initial & Last Name & Degree
Adriana Filimon
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD Sharing Time Frame
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD Sharing Access Criteria
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD Sharing URL
http://vivli.org/
Links:
URL
https://trials.lilly.com/en-US/trial/362875
Description
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Learn more about this trial
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
We'll reach out to this number within 24 hrs